US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

111.16

+1.361.24%

Volume:7K

Turnover:756.48K

Market Cap:93.37M

PE:- -

High:111.16

Open:110.00

Low:108.00

Close:109.80

52wk High:126.40

52wk Low:62.72

Shares:840.00K

Float Shares:840.00K

Volume Ratio:1.72

T/O Rate:0.82%

Dividend:0.22

Dividend Rate:0.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/BIB/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"ProShares Ultra Nasdaq Biotechnology","latestPrice":111.16,"timestamp":1791220851367,"preClose":109.8002,"halted":0,"volume":6914,"delay":0,"changeRate":0.01238431259688045,"floatShares":840000,"shares":840000,"eps":0,"marketStatus":"Trading","change":1.3598,"latestTime":"10-05 13:25:03 EDT","open":110,"high":111.16,"low":108,"amount":756476.78048,"amplitude":0.02878,"askPrice":111.62,"askSize":20,"bidPrice":111.36,"bidSize":120,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791230400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":109.8002,"sharesOutstanding":1040000,"nav":110.3888,"aum":92726592,"dividendRate":0.001976,"bidAskSpread":0.002593,"postHourTrading":{"tag":"盘后","latestPrice":109.76,"preClose":109.8002,"latestTime":"19:30 EDT","volume":14,"amount":1537.8616,"timestamp":1790983802987,"change":-0.0402,"changeRate":-0.000366,"amplitude":0},"volumeRatio":1.724162,"impliedVol":0.4641,"impliedVolPercentile":0.5339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","floatShares":840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.724162,"shares":840000,"dividePrice":0.2197,"high":111.16,"amplitude":0.02878,"preClose":109.8002,"low":108,"week52Low":62.72,"pbRate":"--","week52High":126.399,"institutionHeld":0,"latestPrice":111.16,"committee":0.714286,"eps":0,"divideRate":0.001976,"volume":6914,"delay":0,"ttmEps":0,"open":110,"prevYearClose":79.7794,"prevWeekClose":109.8002,"prevMonthClose":115.4524,"prevQuarterClose":115.4524,"fiveDayClose":115.6276,"twentyDayClose":119.9993,"sixtyDayClose":102.9242},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-23","symbol":"BIB","amount":0.082554,"announcedDate":"2026-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-23","defaultRemindTime":1790170200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-29","payableDate":"2026-09-23","currency":"USD","dateTimestamp":1790136000000,"payDate":"2026-09-29"},{"date":"2026-03-25","symbol":"BIB","amount":0.00714,"announcedDate":"2026-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-25","defaultRemindTime":1774445400000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-25","currency":"USD","dateTimestamp":1774411200000,"payDate":"2026-03-31"},{"date":"2025-12-24","symbol":"BIB","amount":0.134637,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-31"},{"date":"2025-09-24","symbol":"BIB","amount":0.180541,"announcedDate":"2025-09-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-24","defaultRemindTime":1758720600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-24","currency":"USD","dateTimestamp":1758686400000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"BIB","amount":0.170576,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-07-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIB\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-22","recordDate":"2022-12-23","paymentDate":"2022-12-30","value":0.019852,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-28","value":0.038393,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-27","value":0.040324,"currency":"USD"},{"executeDate":"2024-06-26","recordDate":"2024-06-26","paymentDate":"2024-07-03","value":0.26476,"currency":"USD"},{"executeDate":"2024-09-25","recordDate":"2024-09-25","paymentDate":"2024-10-02","value":0.15285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIB\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669123184","title":"Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123184","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123184?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:15","pubTimestamp":1790090123,"startTime":"0","endTime":"0","summary":"• Amgen shares rose following positive Phase 3 OASIZ 301 trial results for dazodalibep.  \n• The company reported an annual revenue of $36.75B and a net profit of $7.71B.  \n• Analysts hold an average price target of $389.14 with a Hold rating.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262180812-market-movers-amgn-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU1983299246.USD","LU2468319806.SGD","BK4585","BK4599","IBB","BIB","PBE","LU2112291526.USD","AMGN","BK4566","PJP","LU0320765992.SGD","BK4581","04332","IE00B4R5TH58.HKD","LU1061106388.HKD","LU0889565916.HKD","LU2089984988.USD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0058720904.USD","BK4534","BK4588","LU0868494617.USD","LU1023059063.AUD","LU0122379950.USD","TBXU","BBH","LU0109394709.USD","LU0289739699.SGD","BK4533","IE00BJJMRZ35.SGD","SG9999001440.SGD","LU1571399168.USD","LU1057294990.SGD","BK4139","LU2242652126.USD","IE00BFTCPJ56.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669821123","title":"Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669821123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669821123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:55","pubTimestamp":1790088920,"startTime":"0","endTime":"0","summary":"Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially und...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242646821.SGD","LU1983299246.USD","IE00B2B36J28.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","AMGN","LU0058720904.USD","IE00BJT1NW94.SGD","BK4139","BK4599","IE0009355771.USD","LU2468319806.SGD","PJP","BBH","IBBQ","BK4534","LU0320765992.SGD","BK4581","LU0868494617.USD","LU1057294990.SGD","LU0122379950.USD","BIB","LU2242652126.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4533","IE00BJJMRZ35.SGD","BK4585","LU0289739699.SGD","BK4588","LU2112291526.USD","IE0002141913.USD","BK4566","LU2089984988.USD","IBB","LU1023059063.AUD","TBXU","SG9999001440.SGD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2462157665.USD","LU1559883803.SGD","LU1674673428.USD","IDNA","IE00B19Z3581.USD","BK4585","VERX","LU1093756325.SGD","LU1674673691.USD","LU2456880835.USD","TBXU","LU2362541513.USD","IE0002270589.USD","IE00B4R5TH58.HKD","IBB","BK4532","LU0256863811.USD","LU1093756168.USD","LU1035775433.USD","LU2089984988.USD","SGXZ57979304.SGD","IE0002141913.USD","LU1069344957.HKD","IE0009355771.USD","LU0823416689.USD","LU0061475181.USD","IE00BZ9MQY76.HKD","PBE","BK4023","BBH","GNMX","IE00B894F039.SGD","BIB","LU0079474960.USD","LU2362540622.SGD","LU0889565916.HKD","LU0289739699.SGD","BK4533","VRTX","IE00B19Z3B42.SGD","LU1585245621.USD","SG9999013999.USD","LU0320765992.SGD","IE00B19Z9P08.USD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU0757428866.USD","IBBQ","IE00B19Z9Z06.USD","LU1778281490.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0109394709.USD","LU1093756325.SGD","IE0009355771.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","LU0256863811.USD","IE00B19Z9Z06.USD","IE00B19Z3581.USD","BK4585","LU1778281490.HKD","LU0079474960.USD","IBB","LU2362541273.HKD","IE0002141913.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1674673428.USD","LU2456880835.USD","BK4023","IE0002270589.USD","BK4567","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","VERX","LU0432979614.USD","GNMX","LU1559883803.SGD","TBXU","BK4139","LU2462157665.USD","LU2362541513.USD","LU0234570918.USD","LU2417539215.USD","LU2089984988.USD","BBH","SG9999013999.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669470171","title":"Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2669470171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669470171?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:48","pubTimestamp":1790084894,"startTime":"0","endTime":"0","summary":"BUZZ-Amgen rises after autoimmune drug meets late-stage trial goal** Shares of drugmaker AmgenAMGN.Orise 2.4% to $402.69** Co says its experimental drug, dazodalibep, for Sjogren's diseasemet the main goalof reducing disease activity in a late-stage trial** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate** Co plans to present detailed results at an upcoming medical meeting** Including session's move, AMGN up 23.1% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1983299246.USD","BK4599","LU0058720904.USD","BBH","IE00BFTCPJ56.SGD","BK4588","IE0002141913.USD","AMGN","IE00B2B36J28.USD","LU2242646821.SGD","PJP","LU2242652126.USD","LU2468319806.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4533","IBB","BK4566","BK4585","TBXU","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","IBBQ","LU1061106388.HKD","LU2089984988.USD","SG9999001440.SGD","LU0889565916.HKD","LU1571399168.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","BK4534","PBE","LU0320765992.SGD","BK4139","LU1023059063.AUD","LU0868494617.USD","BK4581","LU0289739699.SGD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147050","title":"Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147050?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:45","pubTimestamp":1790084715,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Amgen Inc::*AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026*AMGEN: DAZODALIBEP MEETS PRIMARY ENDPOI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSDcc0x9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","TBXU","SG9999001440.SGD","AMGN","IE00B4R5TH58.HKD","PJP","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IBBQ","LU1057294990.SGD","LU2112291526.USD","BK4533","PBE","BK4581","IE00B2B36J28.USD","LU2242646821.SGD","LU2242652126.USD","LU2468319806.SGD","LU1571399168.USD","BIB","LU0289739699.SGD","BBH","IE0009355771.USD","BK4585","LU1983299246.USD","IE00BJT1NW94.SGD","BK4588","LU0058720904.USD","BK4139","LU1023059063.AUD","LU0109394709.USD","BK4534","BK4599","IBB","LU0868494617.USD","LU2089984988.USD","LU1061106388.HKD","LU0122379950.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147177","title":"Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147177?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:36","pubTimestamp":1790084178,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4585","LU0289739699.SGD","BK4599","IE0002141913.USD","LU0109394709.USD","PJP","IE00B2B36J28.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4534","LU1983299246.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","BBH","BK4588","LU2112291526.USD","BK4566","LU1061106388.HKD","LU2242646821.SGD","BK4581","BIB","IE0009355771.USD","LU1057294990.SGD","LU0868494617.USD","PBE","TBXU","IBBQ","SG9999001440.SGD","LU0058720904.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4139","AMGN","BK4533","IBB","LU2089984988.USD","LU2242652126.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","BK4581","TBXU","LU1983299246.USD","PJP","LU1023059063.AUD","LU2468319806.SGD","BK4534","LU2242652126.USD","LU0320765992.SGD","LU0868494617.USD","LU0058720904.USD","IBBQ","LU0289739699.SGD","IE00B2B36J28.USD","PBE","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1057294990.SGD","BK4139","BK4566","LU2242646821.SGD","SG9999001440.SGD","LU1571399168.USD","BK4585","BIB","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1061106388.HKD","IBB","LU2112291526.USD","BBH","IE00BJT1NW94.SGD","BK4599","BK4588","BK4533","LU2089984988.USD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0256863811.USD","GNMX","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2362541513.USD","LU0079474960.USD","PBE","SG9999013999.USD","LU2089984988.USD","LU2362540622.SGD","LU2417539215.USD","LU0417517546.SGD","IE0009355771.USD","BK4533","BK4567","BK4585","LU1093756325.SGD","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","IE00B19Z9P08.USD","LU0823416689.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","VRTX","LU0234570918.USD","IDNA","IBB","LU2236285917.USD","LU2362541273.HKD","BK4588","LU0432979614.USD","LU1093756168.USD","SG9999001176.SGD","BBH","IE0002141913.USD","LU2237438978.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","LU1674673691.USD","IE00B894F039.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2468319806.SGD","IBBQ","IE0009355771.USD","LU1023059063.AUD","BK4566","LU2242646821.SGD","PBE","IE00BJT1NW94.SGD","IBB","LU1061106388.HKD","SG9999001440.SGD","IE00BJJMRZ35.SGD","BK4533","LU0109394709.USD","BK4585","BK4139","LU1571399168.USD","BK4534","LU2089984988.USD","LU1057294990.SGD","LU0868494617.USD","LU0320765992.SGD","LU0058720904.USD","BK4581","BK4599","LU0889565916.HKD","IE00B2B36J28.USD","LU1983299246.USD","LU2112291526.USD","LU2242652126.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","PJP","IE00B4R5TH58.HKD","BK4588","LU0289739699.SGD","TBXU","BIB","BBH","AMGN","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1983299246.USD","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","PBE","LU1057294990.SGD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU1571399168.USD","IE0009355771.USD","BK4599","LU0868494617.USD","BK4533","BK4585","AMGN","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","LU2112291526.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","PJP","BK4534","IBB","LU0058720904.USD","LU2242646821.SGD","BK4588","BK4581","BBH","BK4566","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBB","LU1023059063.AUD","PBE","LU2242652126.USD","LU1571399168.USD","IE0009355771.USD","LU1983299246.USD","LU0889565916.HKD","LU2468319806.SGD","PJP","LU0320765992.SGD","BK4139","BK4581","IE00BFTCPJ56.SGD","LU0058720904.USD","BBH","LU0289739699.SGD","LU2112291526.USD","AMGN","SG9999001440.SGD","LU1057294990.SGD","LU2242646821.SGD","BK4534","TBXU","BK4566","IE0002141913.USD","LU0868494617.USD","IE00BJJMRZ35.SGD","BK4588","IE00BJT1NW94.SGD","BK4599","LU0109394709.USD","BK4585","LU1061106388.HKD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2089984988.USD","BK4533","BIB","LU0122379950.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","IBB","IE00B894F039.SGD","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU1815336091.USD","IE00B19Z9Z06.USD","LU1778281490.HKD","LU2362540622.SGD","SG9999013999.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU1559883803.SGD","LU1674673691.USD","LU2362541513.USD","TBXU","LU2417539215.USD","LU0566484027.USD","IE00BJJMRZ35.SGD","BK4023","IE0002141913.USD","PBE","IE00BJT1NW94.SGD","LU2236285917.USD","LU1069344957.HKD","IE0002270589.USD","LU2468319806.SGD","LU0061475181.USD","IE0009355771.USD","BK4139","IE00B19Z3581.USD","BK4532","LU0757428866.USD","BIB","VRTX","LU2324357040.USD","SG9999001176.USD","LU0079474960.USD","IDNA","SGXZ57979304.SGD","VERX","LU0058720904.USD","BBH","BK4588","LU1035775433.USD","GNMX","SG9999001176.SGD","BK4567","LU2089984988.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1430594728.SGD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU0432979614.USD","IE0009355771.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU2237438978.USD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","IE00B2B36J28.USD","VERX","GNMX","LU0823416689.USD","IE0002141913.USD","BK4023","LU0757428866.USD","BK4139","LU1674673428.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","LU1035775433.USD","LU1674673691.USD","IBB","LU1815336091.USD","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","VRTX","LU1778281490.HKD","PBE","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IBBQ","TBXU","IE00B19Z9P08.USD","LU0889565916.HKD","LU0823416689.USD","IE0002141913.USD","BK4532","PBE","LU0320765992.SGD","IE00BJT1NW94.SGD","IDNA","VRTX","BBH","LU1674673428.USD","BK4567","LU2462157665.USD","LU0061475181.USD","LU0109394709.USD","LU1035775433.USD","LU1069344957.HKD","LU2362541513.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0058720904.USD","LU0256863811.USD","IBB","BK4585","LU0079474960.USD","LU2089984988.USD","LU2468319806.SGD","IE00B19Z3581.USD","BIB","LU0432979614.USD","LU1093756168.USD","BK4588","SG9999013999.USD","IE00BFTCPJ56.SGD","LU1674673691.USD","BK4139","IE0002270589.USD","IE00B19Z9Z06.USD","GNMX","SG9999001176.SGD","LU2237438978.USD","SGXZ57979304.SGD","IE0009355771.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","LU0234570918.USD","LU0109394709.USD","BK4139","IE00B2B36J28.USD","LU2236285917.USD","BK4585","LU1430594728.SGD","IE00B4R5TH58.HKD","LU1069344957.HKD","SG9999001176.SGD","LU0079474960.USD","LU2362540622.SGD","IDNA","IE0002141913.USD","LU0256863811.USD","LU2468319806.SGD","IE00B19Z9P08.USD","TBXU","LU1778281490.HKD","LU2456880835.USD","IE0002270589.USD","LU1093756325.SGD","LU2462157665.USD","LU0417517546.SGD","LU2417539215.USD","SGXZ57979304.SGD","BIB","IBB","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU0823416689.USD","IE00B19Z9Z06.USD","IBBQ","LU1674673691.USD","IE0009355771.USD","LU0289739699.SGD","GNMX","LU2237438978.USD","VRTX","LU2362541273.HKD","LU1585245621.USD","LU1674673428.USD","LU0889565916.HKD","LU2362541513.USD","PBE","IE00B19Z3581.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","LU0432979614.USD","IE00BZ9MQY76.HKD","SG9999001176.SGD","LU0256863811.USD","VRTX","LU0889565916.HKD","LU2362541273.HKD","LU1035775433.USD","LU1069344957.HKD","BBH","BK4139","LU0320765992.SGD","LU1674673428.USD","PBE","LU0058720904.USD","BK4532","IE00BJJMRZ35.SGD","SG9999013999.USD","BK4567","LU0234570918.USD","IE00B19Z9P08.USD","LU2089984988.USD","BIB","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","LU0061475181.USD","SGXZ57979304.SGD","LU2324357040.USD","IE0002141913.USD","LU0079474960.USD","BK4533","IBB","LU2362541513.USD","TBXU","IBBQ","IE0002270589.USD","LU1778281490.HKD","IDNA","BK4588","GNMX","LU2456880835.USD","BK4585","SG9999001176.USD","LU0109394709.USD","LU1585245621.USD","LU2417539215.USD","LU1093756325.SGD","LU2237438978.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999001176.SGD","IBBQ","IE00B19Z3581.USD","BK4532","LU1778281490.HKD","IE00BJT1NW94.SGD","LU0417517546.SGD","BK4585","LU1035775433.USD","LU1069344957.HKD","LU0058720904.USD","LU0432979614.USD","LU0061475181.USD","SGXZ57979304.SGD","SG9999001176.USD","LU1674673428.USD","LU0234570918.USD","LU0256863811.USD","BK4139","IE00BZ9MQY76.HKD","BK4533","LU0823416689.USD","LU2456880835.USD","SG9999013999.USD","LU1093756325.SGD","BBH","IE00B19Z3B42.SGD","TBXU","VRTX","LU1585245621.USD","LU0889565916.HKD","IE0002270589.USD","LU0320765992.SGD","PBE","LU0079474960.USD","IE0002141913.USD","GNMX","BIB","IE00B19Z9P08.USD","LU0109394709.USD","IBB","BK4567","LU1674673691.USD","LU2237438978.USD","LU0289739699.SGD","LU2089984988.USD","LU2236285917.USD","IE00B4R5TH58.HKD","IDNA","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1983299246.USD","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","IVVD","BK4563","PBE","LU1057294990.SGD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","BK4539","LU1571399168.USD","IE0009355771.USD","BK4599","LU0128526141.USD","LU0868494617.USD","LU0029874061.USD","BK4533","BK4585","HCSG","AMGN","XBI","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","BK4137","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","XLV","LU1023059063.AUD","IE00BJJMRZ35.SGD","PJP","BK4534","IBB","HUMA","LU0058720904.USD","LU2242646821.SGD","BK4588","LABU","BBH","BK4566","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU1057294990.SGD","BK4588","BK4581","LU2112291526.USD","BK4139","IE00B2B36J28.USD","BK4599","IE00B4R5TH58.HKD","BK1589","PJP","LU0109394709.USD","BIB","HK0000165453.HKD","LU1061106388.HKD","BK1515","BK4585","LU2089984988.USD","BK1521","IE00BJT1NW94.SGD","TBXU","BK4566","01177","BK1191","BK4533","IE0009355771.USD","LU0320765992.SGD","LU1571399168.USD","LU2242652126.USD","LU0889565916.HKD","AMGN","IBB","IE0002141913.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","IE00BZ08YT58.USD","LU1983299246.USD","BBH","IE00BZ08YR35.GBP","BK4534","LU0289739699.SGD","LU2242646821.SGD","IE00BZ08YS42.EUR","LU1023059063.AUD","LU0122379950.USD","LU0058720904.USD","PBE","IBBQ","SG9999001440.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}